GSK plc (GSK)
NYSE: GSK · IEX Real-Time Price · USD
43.39
+0.03 (0.08%)
May 3, 2024, 10:25 AM EDT - Market open
GSK Revenue
GSK had revenue of $39.41B in the twelve months ending March 31, 2024, with 12.47% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $9.44B with 12.72% year-over-year growth. In the year 2023, GSK had annual revenue of $38.39B with 8.66% growth.
Revenue (ttm)
$39.41B
Revenue Growth
+12.47%
P/S Ratio
2.23
Revenue / Employee
$561,304
Employees
70,212
Market Cap
88.04B USD
Revenue Chart
* The company reports in GBP currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 38.39B | 3.06B | 8.66% |
Dec 31, 2022 | 35.33B | 2.40B | 7.30% |
Dec 31, 2021 | 32.93B | -433.64M | -1.30% |
Dec 31, 2020 | 33.36B | -11.05B | -24.88% |
Dec 31, 2019 | 44.41B | 5.30B | 13.55% |
Dec 31, 2018 | 39.11B | -1.67B | -4.09% |
Dec 31, 2017 | 40.78B | 6.34B | 18.40% |
Dec 31, 2016 | 34.44B | -824.08M | -2.34% |
Dec 31, 2015 | 35.27B | -574.67M | -1.60% |
Dec 31, 2014 | 35.84B | -8.05B | -18.35% |
Dec 31, 2013 | 43.90B | 1.02B | 2.38% |
Dec 31, 2012 | 42.87B | 373.22M | 0.88% |
Dec 31, 2011 | 42.50B | -1.69B | -3.83% |
Dec 31, 2010 | 44.19B | -1.72B | -3.75% |
Dec 31, 2009 | 45.91B | 10.36B | 29.14% |
Dec 31, 2008 | 35.55B | -9.71B | -21.45% |
Dec 31, 2007 | 45.26B | -277.48M | -0.61% |
Dec 31, 2006 | 45.54B | 8.27B | 22.18% |
Dec 31, 2005 | 37.27B | -1.14B | -2.97% |
Dec 31, 2004 | 38.41B | 753.32M | 2.00% |
Dec 31, 2003 | 37.66B | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CVS Health | 357.78B |
McKesson | 301.51B |
Cigna | 195.27B |
HCA Healthcare | 64.97B |
Bristol-Myers Squibb Company | 45.53B |
Gilead Sciences | 27.12B |
Becton, Dickinson and Company | 19.49B |
Regeneron Pharmaceuticals | 13.12B |
GSK News
- 5 hours ago - 5 best blue chip stocks to invest in for sustainable gains in May – excluding Apple Inc. (AAPL) - Invezz
- 19 hours ago - GSK knew about Zantac cancer risk, attorneys tell jury in first trial - Reuters
- 2 days ago - GSK raises full-year profit forecast - Reuters
- 2 days ago - FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How - Forbes
- 2 days ago - FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition' - Market Watch
- 8 days ago - GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology - Reuters
- 16 days ago - GSK says efficacy of its shingles vaccine remains high after years - Reuters
- 6 weeks ago - Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease - GlobeNewsWire